Literature DB >> 16774045

Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.

Jessica Stoeckel1, John G Hay.   

Abstract

Oncolytics Biotech is developing an oncolytic reovirus therapy (Reolysin, Reosyn) for the potential treatment of a variety of Ras-mediated cancers, including glioma and medulloblastoma, pancreatic, prostate, breast, lung, colon, bladder, ovarian and hematological cancers, and melanoma and childhood sarcoma. Phase I/II clinical trials in recurrent malignant glioma began in 2002.

Entities:  

Mesh：

Year:  2006        PMID： 16774045

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  17 in total

1.  Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.

Authors:  Romit Chakrabarty; Hue Tran; Iohann Boulay; Tanya Moran; Audrey Parenteau; Robert Tavcar; Maude Bigras; Allison Hagerman; Sarah Serl; Brad Thompson; Matt Coffey
Journal:  Invest New Drugs       Date:  2013-12       Impact factor: 3.850

2.  Reverse genetics for mammalian reovirus.

Authors:  Karl W Boehme; Miné Ikizler; Takeshi Kobayashi; Terence S Dermody
Journal:  Methods       Date:  2011-07-21       Impact factor: 3.608

3.  Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells.

Authors:  Jeong-Soo Park; Manbok Kim
Journal:  J Microbiol       Date:  2016-12-30       Impact factor: 3.422

4.  Apoptosis induced by mammalian reovirus is beta interferon (IFN) independent and enhanced by IFN regulatory factor 3- and NF-κB-dependent expression of Noxa.

Authors:  Jonathan J Knowlton; Terence S Dermody; Geoffrey H Holm
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

5.  In Vivo Live Imaging of Oncolytic Mammalian Orthoreovirus Expressing NanoLuc Luciferase in Tumor Xenograft Mice.

Authors:  Yuta Kanai; Takahiro Kawagishi; Yoshiharu Matsuura; Takeshi Kobayashi
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

6.  Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo.

Authors:  Adil Mohamed; Derek R Clements; Shashi A Gujar; Patrick W Lee; James R Smiley; Maya Shmulevitz
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

7.  Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.

Authors:  Pooja Gupta-Saraf; Tyler Meseke; Cathy L Miller
Journal:  Virology       Date:  2015-08-08       Impact factor: 3.616

8.  Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus.

Authors:  Annukka A R Antar; Jennifer L Konopka; Jacquelyn A Campbell; Rachel A Henry; Ana L Perdigoto; Bruce D Carter; Ambra Pozzi; Ty W Abel; Terence S Dermody
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

Review 9.  Oncolytic virotherapy for urological cancers.

Authors:  Zahid Delwar; Kaixin Zhang; Paul S Rennie; William Jia
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

10.  Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Authors:  Robert A Adair; Karen J Scott; Sheila Fraser; Fiona Errington-Mais; Hardev Pandha; Matt Coffey; Peter Selby; Graham P Cook; Richard Vile; Kevin J Harrington; Giles Toogood; Alan A Melcher
Journal:  Int J Cancer       Date:  2012-11-26       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.